Cited by 4Mobile Health and mHealth ApplicationsDiabetes Management and EducationDiabetes Management and Research

Organisational models supported by technology for the management of diabetic disease and its complications in a diabetic clinic setting study protocol for a randomised controlled trial targeting type 2 diabetes individuals with non-ideal glycaemic values (Telemechron study)

Open access
Giovanazzi, Alexia, Gios, Lorenzo, Mastellaro, Marina, Gentilini, Maria Adalgisa, Valent, Francesca, Condini, Sara, Bincoletto, Giorgia, Bacchiega, Alessandro +9 more·2023·Trials

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) is a non-communicable disease representing one of the most serious public health challenges of the twenty-first century. Its incidence continues to rise in both developed and developing countries, causing the death of 1.5 million people every year. The use of technology (e.g. smartphone application—App) in the health field has progressively increased as it has been proved to be effective in helping individuals manage their long-term diseases. Therefore, it has the potential to reduce the use of health service and its related costs. The objective of this study is to evaluate the impact of using a digital platform called “TreC Diabete” embedded into a novel organisational asset targeting poorly controlled T2DM individuals in the Autonomous Province of Trento (PAT), Italy. Methods: This trial was designed as a multi-centre, open-label, randomised, superiority study with two parallel groups and a 1:1 allocation ratio. Individuals regularly attending outpatient diabetes clinics, providing informed consent, are randomised to be prescribed TreC Diabete platform as part of their personalised care plan. Healthcare staff members will remotely assess the data shared by the participants through the App by using a dedicated online medical dashboard. The primary end-point is the evaluation of the Hb1Ac level at 12-month post-randomisation. Data will be analysed on an intention-to-treat (ITT) basis. Discussion: This trial is the first conducted in the PAT area for the use of an App specifically designed for individuals with poorly controlled T2DM. If the effects of introducing this specific App within a new organisational asset are positive, the digital platform will represent a possible way for people diagnosed with T2DM to better manage their health in the future. Results will be disseminated through conferences and peer-reviewed journals once the study is completed. Trial registration: ClinicalTrials.gov NCT05629221. Registered on November 29, 2022, prior start of inclusion.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13063-023-07515-6

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The protocol was published in Trials BMC under the title "Organisational models supported by technology for the management of diabetic disease and its complications in a diabetic clinical setting: study protocol for a randomized controlled trial targeting type 2 diabetes individuals with non -ideal glycaemic values (Telemechron study)" and is accessible at the given link.

    “The protocol was also published in Trials BMC under the title “Organisational models supported by technology for the management of diabetic disease and its complications in a diabetic clinical setting: study protocol for a randomized controlled trial targeting type 2 diabetes individuals with non -ideal glycaemic values (Telemechron study) and is accessible at this link: https://trialsjournal.biom”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Giovanazzi, A., Gios, L., Mastellaro, M., Gentilini, M. A., Valent, F., Condini, S., Bincoletto, G., Bacchiega, A., Zorzi, A., Malfatti, G., Perini, F., Eccher, C., Marchesoni, M., Dall’Alda, M., Orrasch, M., Conforti, D., & Inchiostro, S.
Affiliations
  • Provincia Autonoma di Trento (IT)
  • Azienda sanitaria universitaria Friuli Centrale (IT)
  • University of Trento (IT)
  • Fondazione Bruno Kessler (IT)
Corresponding author
Inchiostro, Sandro
Venue
Trials
Published
2023-08-10
Volume
24
Issue
1
Pages
513-513
ISSN
1745-6215 (ISSN-L)
OpenAlex
W4385740300
Cited by
4
References
30
Citations by year
2025: 3 · 2024: 1
FWCI
1.42
Type
journal article
Language
en
Open access
Locations
  • Trials (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Iris (University of Trento) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Department of Health of the Italian National Health System (NET-2018-12367206)
  • Provincia Autonoma di Trento
Topics
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, uncontrolled diabetes, digital health platforms, mobile application, HbA1c, diabetes self-management, remote patient monitoring, diabetes outpatient clinic, telemedicine, health care organization, individualized care plans
MeSH terms
Equivalence Trials as Topic, Diabetes Mellitus, Type 2, Humans, Italy, Technology, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Models, Organizational, Mobile Applications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review